BIOCRYST PHARMACEUTICALS INC's ticker is BCRX and the CUSIP is 09058V103. A total of 199 filers reported holding BIOCRYST PHARMACEUTICALS INC in Q3 2021. The put-call ratio across all filers is 0.63 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $13,055,655 | +0.5% | 1,844,019 | -0.0% | 0.02% | 0.0% |
Q2 2023 | $12,985,660 | -15.6% | 1,844,554 | +0.0% | 0.02% | -18.2% |
Q1 2023 | $15,379,577 | -27.4% | 1,844,074 | 0.0% | 0.02% | -31.2% |
Q4 2022 | $21,169,970 | -9.0% | 1,844,074 | -0.1% | 0.03% | -15.8% |
Q3 2022 | $23,261,000 | +18.8% | 1,846,174 | -0.2% | 0.04% | +22.6% |
Q2 2022 | $19,573,000 | -34.9% | 1,850,024 | -0.0% | 0.03% | -24.4% |
Q1 2022 | $30,086,000 | +17.5% | 1,850,342 | +0.0% | 0.04% | +20.6% |
Q4 2021 | $25,616,000 | -3.7% | 1,849,524 | -0.0% | 0.03% | -12.8% |
Q3 2021 | $26,590,000 | -9.1% | 1,850,354 | 0.0% | 0.04% | -11.4% |
Q2 2021 | $29,254,000 | +55.5% | 1,850,354 | 0.0% | 0.04% | +41.9% |
Q1 2021 | $18,818,000 | +23.7% | 1,850,354 | -9.4% | 0.03% | +14.8% |
Q4 2020 | $15,213,000 | +116.9% | 2,042,099 | 0.0% | 0.03% | +92.9% |
Q3 2020 | $7,015,000 | -27.9% | 2,042,099 | 0.0% | 0.01% | -36.4% |
Q2 2020 | $9,730,000 | +132.7% | 2,042,099 | -2.4% | 0.02% | +83.3% |
Q1 2020 | $4,182,000 | – | 2,091,269 | – | 0.01% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
DG Capital Management, LLC | 1,186,726 | $4,076,000 | 2.45% |
Sarissa Capital Management LP | 4,861,000 | $16,697,000 | 1.97% |
Ghost Tree Capital, LLC | 1,950,000 | $6,698,000 | 1.94% |
ORACLE INVESTMENT MANAGEMENT INC | 2,525,857 | $8,676,000 | 1.14% |
Eversept Partners, LP | 1,143,211 | $3,926,930 | 0.87% |
DAFNA Capital Management LLC | 749,051 | $2,573,000 | 0.84% |
KNOTT DAVID M | 397,361 | $1,365,000 | 0.80% |
Parkman Healthcare Partners LLC | 800,740 | $2,751,000 | 0.73% |
ACUTA CAPITAL PARTNERS, LLC | 660,000 | $2,267,000 | 0.62% |
Formidable Asset Management, LLC | 578,200 | $1,949,000 | 0.57% |